Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 2/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8936130 | 0.86 | NR1H2 (0.42) | MEN1KMT2ANR1H2ATMPARP1 | |
| SCHEMBL25569896 | 0.86 | ATM (0.37) | MEN1KMT2ANR1H2ATMPARP1 | |
| SCHEMBL9696891 | 0.83 | MEN1 (0.34) | MEN1KMT2ANR1H2ATMPARP1 | |
| SCHEMBL29280769 | 0.83 | MEN1 (0.34) | MEN1KMT2ANR1H2ATMPARP1 | |
| SCHEMBL19074545 | 0.83 | MEN1 (0.34) | MEN1KMT2ANR1H2ATMPARP1 | |
| SCHEMBL13286306 | 0.81 | CHRM2 (0.39) | DDB1CRBNMEN1KMT2ANR1H2 | |
| SCHEMBL19152862 | 0.81 | CHRM2 (0.39) | DDB1CRBNMEN1KMT2ANR1H2 | |
| SCHEMBL12300133 | 0.81 | HSD11B1 (0.34) | MEN1KMT2ANR1H2ATMPARP1 | |
| SCHEMBL18700390 | 0.81 | ELANE (0.36) | MEN1KMT2AATMPARP1 | |
| SCHEMBL585407 | 0.80 | MEN1 (0.33) | MEN1KMT2ANR1H2ATMPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050256166-A1 | Nitrogen-containing compounds | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-11-17 | — | — | US | disclosed |
| EP-1535906-A1 | NITROGEN-CONTAINING COMPOUNDS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256166-A1 | Nitrogen-containing compounds | DPP4, DPP3, DPP8 | HSD17B10 350/4885DDB1 601/4885CRBN 1596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.